VRDN FY 2013 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$2B

FY 2013 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-2.0% YoY

Gross Profit

$2M42.1% margin

Operating Income

-$196,213-4.5% margin

Net Income

-$2M-50.0% margin

EPS (Diluted)

$-11.48

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$1M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$4M

Total Liabilities

$2M

Stockholders' Equity

$2M

Cash & Equivalents

$209,348

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$4M	-2.0%
Gross Profit	$2M	$1M	+33.3%
Operating Income	-$196,213	-$4M	+95.1%
Net Income	-$2M	-$7M	+70.1%